Ming Ren Toh, Gerald Xuan Zhong Ng, Ishita Goel, Shao Wei Lam, Jun Tian Wu, Chun Fan Lee, Marcus Eng Hock Ong, David Bruce Matchar, Ngiap Chuan Tan, Chian Min Loo, Mariko Siyue Koh
{"title":"哮喘处方趋势、吸入器依从性和结果:对多种族亚裔哮喘人群的真实世界数据分析。","authors":"Ming Ren Toh, Gerald Xuan Zhong Ng, Ishita Goel, Shao Wei Lam, Jun Tian Wu, Chun Fan Lee, Marcus Eng Hock Ong, David Bruce Matchar, Ngiap Chuan Tan, Chian Min Loo, Mariko Siyue Koh","doi":"10.1038/s41533-024-00391-w","DOIUrl":null,"url":null,"abstract":"<p><p>Inhaled corticosteroid (ICS) is the mainstay therapy for asthma, but general adherence is low. There is a paucity of real-world inhaler prescribing and adherence data from Asia and at the population level. To address these gaps, we performed a real-world data analysis of inhaler prescribing pattern and adherence in a multi-ethnic Asian asthma cohort and evaluated the association with asthma outcomes. We performed a retrospective analysis of adult asthma patients (aged ≥18 years) treated in the primary and specialist care settings in Singapore between 2015 to 2019. Medication adherence was measured using the medication possession ratio (MPR), and categorised into good adherence (MPR 0.75-1.2), poor adherence (MPR 0.75) or medication oversupply (MPR > 1.2). All statistical analyses were performed using R Studio. 8023 patients, mean age 57 years, were evaluated between 2015 and 2019. Most patients were receiving primary care (70.4%) and on GINA step 1-3 therapies (78.2%). ICS-long-acting beta-2 agonist (ICS-LABA) users increased over the years especially in the primary care, from 33% to 52%. Correspondingly, inpatient admission and ED visit rates decreased over the years. Between 2015 and 2019, the proportion of patients with poor adherence decreased from 12.8% to 10.5% (for ICS) and from 30.0% to 26.8% (for ICS-LABA) respectively. Factors associated with poor adherence included minority ethnic groups (Odds ratio of MPR 0.75-1.2: 0.73-0.93; compared to Chinese), presence of COPD (OR 0.75, 95% CI 0.59-0.96) and GINA step 4 treatment ladder (OR 0.71, 95% CI 0.61-0.85). Factors associated with good adherence were male gender (OR 1.14, 95% CI 1.01-1.28), single site of care (OR 1.22 for primary care and OR 1.76 for specialist care), GINA step 2 treatment ladder (OR 1.28, 95% CI 1.08-1.50). Good adherence was also associated with less frequent inpatient admission (OR 0.91, 95% CI 0.84-0.98), greater SABA overdispensing (OR 1.66, 95% CI 1.47-1.87) and oral corticosteroids use (OR 1.10, 95% CI 1.05-1.14). Inhaled corticosteroid (ICS) adherence has improved generally, however, poor adherence was observed for patients receiving asthma care in both primary and specialist care, and those from the minority ethnicities.</p>","PeriodicalId":19470,"journal":{"name":"NPJ Primary Care Respiratory Medicine","volume":"34 1","pages":"35"},"PeriodicalIF":3.1000,"publicationDate":"2024-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11532544/pdf/","citationCount":"0","resultStr":"{\"title\":\"Asthma prescribing trends, inhaler adherence and outcomes: a Real-World Data analysis of a multi-ethnic Asian Asthma population.\",\"authors\":\"Ming Ren Toh, Gerald Xuan Zhong Ng, Ishita Goel, Shao Wei Lam, Jun Tian Wu, Chun Fan Lee, Marcus Eng Hock Ong, David Bruce Matchar, Ngiap Chuan Tan, Chian Min Loo, Mariko Siyue Koh\",\"doi\":\"10.1038/s41533-024-00391-w\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Inhaled corticosteroid (ICS) is the mainstay therapy for asthma, but general adherence is low. There is a paucity of real-world inhaler prescribing and adherence data from Asia and at the population level. To address these gaps, we performed a real-world data analysis of inhaler prescribing pattern and adherence in a multi-ethnic Asian asthma cohort and evaluated the association with asthma outcomes. We performed a retrospective analysis of adult asthma patients (aged ≥18 years) treated in the primary and specialist care settings in Singapore between 2015 to 2019. Medication adherence was measured using the medication possession ratio (MPR), and categorised into good adherence (MPR 0.75-1.2), poor adherence (MPR 0.75) or medication oversupply (MPR > 1.2). All statistical analyses were performed using R Studio. 8023 patients, mean age 57 years, were evaluated between 2015 and 2019. Most patients were receiving primary care (70.4%) and on GINA step 1-3 therapies (78.2%). ICS-long-acting beta-2 agonist (ICS-LABA) users increased over the years especially in the primary care, from 33% to 52%. Correspondingly, inpatient admission and ED visit rates decreased over the years. Between 2015 and 2019, the proportion of patients with poor adherence decreased from 12.8% to 10.5% (for ICS) and from 30.0% to 26.8% (for ICS-LABA) respectively. Factors associated with poor adherence included minority ethnic groups (Odds ratio of MPR 0.75-1.2: 0.73-0.93; compared to Chinese), presence of COPD (OR 0.75, 95% CI 0.59-0.96) and GINA step 4 treatment ladder (OR 0.71, 95% CI 0.61-0.85). Factors associated with good adherence were male gender (OR 1.14, 95% CI 1.01-1.28), single site of care (OR 1.22 for primary care and OR 1.76 for specialist care), GINA step 2 treatment ladder (OR 1.28, 95% CI 1.08-1.50). Good adherence was also associated with less frequent inpatient admission (OR 0.91, 95% CI 0.84-0.98), greater SABA overdispensing (OR 1.66, 95% CI 1.47-1.87) and oral corticosteroids use (OR 1.10, 95% CI 1.05-1.14). Inhaled corticosteroid (ICS) adherence has improved generally, however, poor adherence was observed for patients receiving asthma care in both primary and specialist care, and those from the minority ethnicities.</p>\",\"PeriodicalId\":19470,\"journal\":{\"name\":\"NPJ Primary Care Respiratory Medicine\",\"volume\":\"34 1\",\"pages\":\"35\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2024-11-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11532544/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"NPJ Primary Care Respiratory Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s41533-024-00391-w\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PRIMARY HEALTH CARE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"NPJ Primary Care Respiratory Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41533-024-00391-w","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PRIMARY HEALTH CARE","Score":null,"Total":0}
引用次数: 0
摘要
吸入皮质类固醇(ICS)是治疗哮喘的主要方法,但一般的依从性较低。来自亚洲和人口层面的真实世界吸入器处方和依从性数据很少。为了填补这些空白,我们对亚洲多种族哮喘队列中的吸入器处方模式和依从性进行了真实世界数据分析,并评估了与哮喘结果的关联。我们对 2015 年至 2019 年期间在新加坡初级和专科医疗机构接受治疗的成年哮喘患者(年龄≥18 岁)进行了回顾性分析。用药依从性采用药物持有率(MPR)进行测量,并分为良好依从性(MPR 0.75-1.2)、不良依从性(MPR 0.75)或药物过量(MPR > 1.2)。所有统计分析均使用 R Studio 进行。在 2015 年至 2019 年期间,共有 8023 名患者接受了评估,平均年龄为 57 岁。大多数患者接受初级保健(70.4%)和 GINA 1-3 级疗法(78.2%)。ICS-长效β-2受体激动剂(ICS-LABA)使用者逐年增加,尤其是在初级医疗机构,从33%增至52%。相应地,住院率和急诊室就诊率逐年下降。2015年至2019年期间,依从性差的患者比例分别从12.8%降至10.5%(ICS)和从30.0%降至26.8%(ICS-LABA)。与依从性差相关的因素包括少数民族(MPR 0.75-1.2 的比值比:0.73-0.93;与中国人相比)、是否患有慢性阻塞性肺病(OR 0.75,95% CI 0.59-0.96)和 GINA 第 4 步治疗阶梯(OR 0.71,95% CI 0.61-0.85)。与良好依从性相关的因素包括男性(OR 1.14,95% CI 1.01-1.28)、单一医疗机构(初级医疗机构 OR 1.22,专科医疗机构 OR 1.76)、GINA 第 2 步治疗阶梯(OR 1.28,95% CI 1.08-1.50)。良好的依从性还与较少的住院次数(OR 0.91,95% CI 0.84-0.98)、较多的 SABA 过度配药(OR 1.66,95% CI 1.47-1.87)和口服皮质类固醇的使用(OR 1.10,95% CI 1.05-1.14)有关。吸入皮质类固醇(ICS)的依从性总体上有所改善,但在接受初级和专科治疗的哮喘患者以及少数民族患者中,依从性较差。
Asthma prescribing trends, inhaler adherence and outcomes: a Real-World Data analysis of a multi-ethnic Asian Asthma population.
Inhaled corticosteroid (ICS) is the mainstay therapy for asthma, but general adherence is low. There is a paucity of real-world inhaler prescribing and adherence data from Asia and at the population level. To address these gaps, we performed a real-world data analysis of inhaler prescribing pattern and adherence in a multi-ethnic Asian asthma cohort and evaluated the association with asthma outcomes. We performed a retrospective analysis of adult asthma patients (aged ≥18 years) treated in the primary and specialist care settings in Singapore between 2015 to 2019. Medication adherence was measured using the medication possession ratio (MPR), and categorised into good adherence (MPR 0.75-1.2), poor adherence (MPR 0.75) or medication oversupply (MPR > 1.2). All statistical analyses were performed using R Studio. 8023 patients, mean age 57 years, were evaluated between 2015 and 2019. Most patients were receiving primary care (70.4%) and on GINA step 1-3 therapies (78.2%). ICS-long-acting beta-2 agonist (ICS-LABA) users increased over the years especially in the primary care, from 33% to 52%. Correspondingly, inpatient admission and ED visit rates decreased over the years. Between 2015 and 2019, the proportion of patients with poor adherence decreased from 12.8% to 10.5% (for ICS) and from 30.0% to 26.8% (for ICS-LABA) respectively. Factors associated with poor adherence included minority ethnic groups (Odds ratio of MPR 0.75-1.2: 0.73-0.93; compared to Chinese), presence of COPD (OR 0.75, 95% CI 0.59-0.96) and GINA step 4 treatment ladder (OR 0.71, 95% CI 0.61-0.85). Factors associated with good adherence were male gender (OR 1.14, 95% CI 1.01-1.28), single site of care (OR 1.22 for primary care and OR 1.76 for specialist care), GINA step 2 treatment ladder (OR 1.28, 95% CI 1.08-1.50). Good adherence was also associated with less frequent inpatient admission (OR 0.91, 95% CI 0.84-0.98), greater SABA overdispensing (OR 1.66, 95% CI 1.47-1.87) and oral corticosteroids use (OR 1.10, 95% CI 1.05-1.14). Inhaled corticosteroid (ICS) adherence has improved generally, however, poor adherence was observed for patients receiving asthma care in both primary and specialist care, and those from the minority ethnicities.
期刊介绍:
npj Primary Care Respiratory Medicine is an open access, online-only, multidisciplinary journal dedicated to publishing high-quality research in all areas of the primary care management of respiratory and respiratory-related allergic diseases. Papers published by the journal represent important advances of significance to specialists within the fields of primary care and respiratory medicine. We are particularly interested in receiving papers in relation to the following aspects of respiratory medicine, respiratory-related allergic diseases and tobacco control:
epidemiology
prevention
clinical care
service delivery and organisation of healthcare (including implementation science)
global health.